Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Fenebrutinib targets cells in the immune system known as B cells and microglia
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Subscribe To Our Newsletter & Stay Updated
